ArticleBlood2008
CYP4F2 genetic variant alters required warfarin dose.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01520402 (Quantitative Pharmacogenomics of the Anticoagulant Response to Warfarin in Healthy Subjects), which is not on this map. Cited by 224 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Quantitative Pharmacogenomics of the Anticoagulant Response to Warfarin in Healthy Subjects
Who cites it
224 citing papers in PubMed, 7 syntheses or guidelines pooled it, 522 citations in OpenAlex.
- Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.The Journal of molecular diagnostics : JMD · 2020Guideline
- Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.Clinical pharmacology and therapeutics · 2019Pooled it
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.Clinical pharmacology and therapeutics · 2017Guideline
- Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.Saudi medical journal · 2016Pooled it
- The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.PloS one · 2016Pooled it
- Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.Clinical pharmacology and therapeutics · 2012Pooled it
- Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.PloS one · 2012Pooled it
- CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.The pharmacogenomics journal · 2020Trial
- Trial
- A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation.PloS one · 2015Trial
- Trial
- The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery.Journal of thrombosis and thrombolysis · 2014Trial
- CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.European journal of clinical pharmacology · 2013Trial
- Apple juice greatly reduces systemic exposure to atenolol.British journal of clinical pharmacology · 2013Trial
- Trial
- Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.The pharmacogenomics journal · 2012Trial
- Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.Journal of thrombosis and thrombolysis · 2012Trial
- Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study.European journal of clinical pharmacology · 2012Trial
- Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.Clinical medicine & research · 2011Trial
- Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.European journal of clinical pharmacology · 2011Trial
164 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
Abstract
Warfarin is an effective, commonly prescribed anticoagulant used to treat and prevent thrombotic events. Because of historically high rates of drug-associated adverse events, warfarin remains underprescribed. Further, interindividual variability in therapeutic dose mandates frequent monitoring until target anticoagulation is achieved. Genetic polymorphisms involved in warfarin metabolism and sensitivity have been implicated in variability of dose. Here, we describe a novel variant that influences warfarin requirements. To identify additional genetic variants that contribute to warfarin requirements, screening of DNA variants in additional genes that code for drug-metabolizing enzymes and drug transport proteins was undertaken using the Affymetrix drug-metabolizing enzymes and transporters panel. A DNA variant (rs2108622; V433M) in cytochrome P450 4F2 (CYP4F2) was associated with warfarin dose in 3 independent white cohorts of patients stabilized on warfarin representing diverse geographic regions in the United States and accounted for a difference in warfarin dose of approximately 1 mg/day between CC and TT subjects. Genetic variation of CYP4F2 was associated with a clinically relevant effect on warfarin requirement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.